Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04427293
Title Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors University of Illinois at Chicago
Indications

triple-receptor negative breast cancer

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.